Why the study?
Does zolpidem inhibit hERG K+ channels and prolong action potential duration in cellular models?
Does zolpidem inhibit hERG K+ channels and prolong action potential duration in cellular models?
Zolpidem inhibits cardiac hERG K+ channels and prolongs action potential duration, providing a mechanistic basis for its clinical association with acquired long QT syndrome.
No takes yet. Share an insight, caveat, or question.
Raises possibility of QT risk with zolpidem; leaves open clinical implications pending human data.
Jehle et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: